Journals / Turkish Neurosurgery / 2012 / Cilt: 22 - Sayı: 5

Akromegali hastalarında ilk cerrahi tedavi başarısındaki artış

Improvement in remission rates of the first operation in acromegalic patients

Pages
645–650
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

ConclusIon: The clinical recognition of acromegaly and outcomes of single experienced surgeons in specialized centers have significantly improved over the last years.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: The aim of the study was to determine the remission rates of the first operation with respect to the number of surgeons and the parameters important for the prediction of the success.
📊
Key Findings & Data:MaterIal and Methods: The study cohort consisted of 180 acromegalic patients who presented over a 29 year.
💡
Conclusion & Impact:ConclusIon: The clinical recognition of acromegaly and outcomes of single experienced surgeons in specialized centers have significantly improved over the last years.
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

AIM: The aim of the study was to determine the remission rates of the first operation with respect to the number of surgeons and the parameters important for the prediction of the success. MaterIal and Methods: The study cohort consisted of 180 acromegalic patients who presented over a 29 year. All the patients had undergone transnasal transsphenoidal adenomectomy and then octreotide treatment and/or radiotherapy were applied to the patients who were not cured. Remission criteria was accepted as nadir GH<1 &#956;g/L with oral glucose tolerance test (OGTT) and normal IGF-1 with respect to age and gender. Results: The postoperative median follow up period was 84 months (range 6-372 months). The remission rate of the first operation before 2003 was 20%, but this rate increased to 51% after 2003 (p=0.018). The most impressive improvement was due to the single experienced surgeon (49% vs. 5.3%) (p<0.001). The success of the first operation was determined by the tumor size, microadenomas were more successfully treated than macroadenomas (p=0.014). The prevalence of discordance between GH and IGF-1 was 24% in patients cured after first surgery. ConclusIon: The clinical recognition of acromegaly and outcomes of single experienced surgeons in specialized centers have significantly improved over the last years.

Özet

AMAÇ: Akromegali tedavisinde ilk cerrahi tedavinin başarısını, beyin cerrahının deneyimine, sayısına ve remisyon oranlarını etkileyebilecek diğer parametrelere göre belirlemektir. YÖNTEM ve GEREÇLER: 29 yıl süresince 180 akromegalik hasta (86 kadın, 94 erkek) değerlendirilmiştir. Tüm hastalara transnazal/transsfenoidal adenomektomi yapılmış, kür sağlanamayanlara octreotid tedavisi ve/veya radyoterapi uygulanmıştır. Remisyon kriteri olarak, IGF-1’in yaş ve cinsiyete göre normal sınırlarda olması ve Glukoz-büyüme hormonu baskılanma testinde büyüme hormonunun <1’e baskılanması kabul edilmiştir. BULGULAR: Postoperatif ortanca (minimum-maksimum) takip süresi 84 (6-372) aydır. İlk operasyonun remisyon oranı 2003’ten önce %20 iken 2003’ten sonra %51’e yükselmiştir (p= 0,018). Oranlardaki en belirgin düzelme, tek deneyimli cerrah ile sağlanmıştır (%49 ve %5,3) (p<0,001). İlk operasyonun başarısı, tümör boyutundan etkilenmektedir. Mikroadenomlar, makroadenomlara göre ilk operasyon sonrası (p= 0,014) daha başarılı bir şekilde tedavi edilmektedir. Büyüme hormonu-IGF-1 diskordansı, ilk cerrahi sonrası kür olanlarda %24 oranında bulunmuştur. SONUÇ: Hipofiz cerrahisinin, referans merkezlerinde tek deneyimli cerrah tarafından yapılması sıkı remisyon kriterleri kullanıldığında bile son yıllarda akromegali tedavisinde önemli gelişmeler sağlanmasına katkıda bulunmuştur.

🔖

Cite This Article

DEMİR, Ö., GEDIK, V., ÇORAPÇIOĞLU, D., EMRAL, R., UNLU, M. A., ERDOĞAN, M. F., GÜLLÜ, S., UYSAL, A. R., BAŞKAL, N. (2012). Akromegali hastalarında ilk cerrahi tedavi başarısındaki artış. Turkish Neurosurgery, Cilt: 22 - Sayı: 5, 645–650. https://ajindex.com/articles/396766

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB: Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results. J Clin Endocrinol Metab 83(10):3411-3418, 1998 2. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA: Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf ) 50:561-567, 1999 3. Beauregard C, Truong U, Hardy J, Serri O: Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf ) 58(1):86-91, 2003 4. Bengtsson BA, Edén S, Ernest I, Odén A, Sjögren B: Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223(4):327-335, 1988 5. Biermasz Nienke R, Roelfsema Ferdinand, Pereira Alberto M, Romijn Johannes A: Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly. Expert review of pharmacoeconomics & outcomes research. 9(3):2232-2234, 2009 6. Boguszewski CL: Molecular heterogeneity of human GH: From basic research to clinical implications. J Endocrinol Invest 26(3):274-288, 2003 7. Ciric I, Ragin A, Baumgartner C, Pierce D: Complications of transsphenoidal surgery: Results of a national survey, review of the literature, and personal experience. Neurosurgery 40:225-236, 1997 8. Clayton RN: How many surgeons to operate on acromegalic patients? Clin Endocrinol (Oxf ) 50:557-559, 1999 9. Clayton RN, Stewart PM, Shalet SM, Wass JA: Pituitary surgery for acromegaly: Should be done by specialists. BMJ 319: 588-589, 1999 10. Cook DM, Ezzat S, Katznelson L, Kleinberg DL, Laws ER Jr, Nippoldt TB, Swearingen B, Vance ML: AACE Acromegaly Guidelines Task Force. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract 10(3):213-225, 2004 11. Costa AC, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC: Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: Should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 87(7):3142-3147, 2002 12. Cozzi R, Attanasio R, Grottoli S, Pagani G, Loli P, Gasco V, Pedroncelli AM, Montini M, Ghigo E: Treatment of acromegaly with SS analogues: Should GH and IGF-I target levels be lowered to assert a tight control of the disease? J Endocrinol Invest 27(11):1040-1047, 2004 13. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP